Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Equity Average (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Equity Average for 12 consecutive years, with $228.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 20.61% to $228.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $228.8 million, a 20.61% increase, with the full-year FY2020 number at -$263.8 million, down 91.55% from a year prior.
  • Equity Average was $228.8 million for Q3 2025 at Theravance Biopharma, up from $195.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $461.2 million in Q4 2022 to a low of -$350.6 million in Q2 2022.
  • A 5-year average of $72.7 million and a median of $189.7 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: crashed 86.97% in 2021, then skyrocketed 302.46% in 2023.
  • Theravance Biopharma's Equity Average stood at -$312.0 million in 2021, then skyrocketed by 247.83% to $461.2 million in 2022, then crashed by 42.94% to $263.1 million in 2023, then tumbled by 31.37% to $180.6 million in 2024, then rose by 26.67% to $228.8 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Equity Average are $228.8 million (Q3 2025), $195.4 million (Q2 2025), and $170.8 million (Q1 2025).